{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:15:42Z","timestamp":1783577742284,"version":"3.55.0"},"reference-count":46,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,12,18]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To describe the efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) in a post-hoc analysis of randomised controlled trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were collected from patients in seven tofacitinib studies: six phase III (four RA, two PsA) and one phase II study (AS), and grouped into five analysis populations based on rheumatic disease diagnosis and category of prior inadequate response (IR) to treatment: conventional synthetic disease-modifying antirheumatic drugs-IR (RA and PsA), tumour necrosis factor inhibitors-IR (RA and PsA), or non-steroidal anti-inflammatory drugs-IR (AS). Only patients who received tofacitinib 5 or 10 mg twice daily or placebo were included. Pain assessments included: Patient\u2019s Assessment of Arthritis Pain, Short-Form Health Survey 36v2 Question (Q)7 and Bodily Pain domain, Ankylosing Spondylitis Quality of Life Q9 and Q14, EuroQol Five Dimensions Pain\/Discomfort dimension and Bath Ankylosing Spondylitis Disease Activity Index Q2 and Q3. Data were reported to month 6 (placebo to month 3) in the RA and PsA populations, and week 12 (tofacitinib and placebo) in the AS population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 3330 patients were included in this analysis. In the RA and PsA populations, pain improvements in tofacitinib-treated patients compared with placebo were observed at the earliest time point assessed and at month 3 (maintained to month 6). In the AS population, pain improvements compared with placebo were observed at week 12.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Tofacitinib was associated with rapid and sustained improvements across multiple pain measures in patients with inflammatory rheumatic musculoskeletal diseases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-001042","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T04:15:27Z","timestamp":1580789727000},"page":"e001042","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00960440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01786668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00960440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01786668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00814307","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alexis","family":"Ogdie","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, UZ Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-8501","authenticated-orcid":false,"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[{"name":"Glasgow Biomedical Research Centre, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Rheumatology Research Group, Swedish Medical Center and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Baer","sequence":"additional","affiliation":[{"name":"Baer Weinberg MPC, Scarborough, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Lukic","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kwok","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ann","family":"Hsu","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Maniccia","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"key":"2025090312173897000_6.1.e001042.1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/acr.20005","article-title":"Report of the American College of Rheumatology Pain Management Task Force","volume":"62","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312173897000_6.1.e001042.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10515"},{"key":"2025090312173897000_6.1.e001042.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170150"},{"key":"2025090312173897000_6.1.e001042.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025090312173897000_6.1.e001042.5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180014","article-title":"Pain and pain mechanisms in patients with inflammatory arthritis: a Danish nationwide cross-sectional DANBIO registry survey","volume":"12","author":"Rifbjerg-Madsen","year":"2017","journal-title":"PLoS One"},{"key":"2025090312173897000_6.1.e001042.6","doi-asserted-by":"crossref","first-page":"8564215","DOI":"10.1155\/2018\/8564215","article-title":"Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets\u2014a focus on the JAK-STAT pathway","volume":"2018","author":"Salaffi","year":"2018","journal-title":"Pain Res Manag"},{"key":"2025090312173897000_6.1.e001042.7","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X11408999"},{"key":"2025090312173897000_6.1.e001042.8","article-title":"Il-4, JAK-STAT signaling, and pain","volume":"2","author":"Busch-Dienstfertig","year":"2013","journal-title":"JAKSTAT"},{"key":"2025090312173897000_6.1.e001042.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141386"},{"key":"2025090312173897000_6.1.e001042.10","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1002\/acr.20543","article-title":"Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)","volume":"63","author":"Hawker","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312173897000_6.1.e001042.11","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200012150-00008"},{"key":"2025090312173897000_6.1.e001042.12","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"2025090312173897000_6.1.e001042.13","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"2025090312173897000_6.1.e001042.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2025090312173897000_6.1.e001042.15","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090312173897000_6.1.e001042.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20"},{"key":"2025090312173897000_6.1.e001042.17","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-12-102","article-title":"Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs --a systematic review and network meta-analysis","volume":"12","author":"Jansen","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"2025090312173897000_6.1.e001042.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057901"},{"key":"2025090312173897000_6.1.e001042.19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/acr.22256","article-title":"Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study","volume":"66","author":"Gladman","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312173897000_6.1.e001042.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091093"},{"key":"2025090312173897000_6.1.e001042.21","first-page":"CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","volume":"4","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Systemic Reviews"},{"key":"2025090312173897000_6.1.e001042.22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.22453","article-title":"Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial","volume":"67","author":"Strand","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312173897000_6.1.e001042.23","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0825-9"},{"key":"2025090312173897000_6.1.e001042.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev442"},{"key":"2025090312173897000_6.1.e001042.25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000308","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial","volume":"2","author":"Strand","year":"2016","journal-title":"RMD Open"},{"key":"2025090312173897000_6.1.e001042.26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23004","article-title":"Tofacitinib in combination with conventional disease\u2010modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient\u2010reported outcomes from a phase III randomized controlled trial","volume":"69","author":"Strand","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312173897000_6.1.e001042.27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2025090312173897000_6.1.e001042.28","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2025090312173897000_6.1.e001042.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"2025090312173897000_6.1.e001042.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.37691"},{"key":"2025090312173897000_6.1.e001042.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207201"},{"key":"2025090312173897000_6.1.e001042.32","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5007-09.2010"},{"key":"2025090312173897000_6.1.e001042.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"2025090312173897000_6.1.e001042.34","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"2025090312173897000_6.1.e001042.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"2025090312173897000_6.1.e001042.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2025090312173897000_6.1.e001042.37","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312173897000_6.1.e001042.38","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312173897000_6.1.e001042.39","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2025090312173897000_6.1.e001042.40","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025090312173897000_6.1.e001042.41","first-page":"S64","article-title":"Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander\/Newcastle Enthesitis index (Mei), Leeds Enthesitis index (LEI), spondyloarthritis research Consortium of Canada (SPARCC), Maastricht ankylosing spondylitis Enthesis score (MASES), Leeds Dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness Therapy-Fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI)","volume":"63 Suppl 11","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312173897000_6.1.e001042.42","unstructured":"Ware JE . User\u2019s Manual for the SF-36v2\u00ae Health Survey Second Edition. Lincoln, RI: QualityMetric Incorporated, 2007."},{"key":"2025090312173897000_6.1.e001042.43","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.12"},{"key":"2025090312173897000_6.1.e001042.44","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: OPAL Beyond, a randomized, double blind, placebo-controlled, phase 3 trial [abstract]","volume":"68(Suppl_10)","author":"Gladman","year":"2016","journal-title":"Arthritis Rheum"},{"key":"2025090312173897000_6.1.e001042.45","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic DMARDs: a randomized, placebo-controlled phase 3 trial [abstract]","volume":"68(Suppl_10)","author":"Mease","year":"2016","journal-title":"Arthritis Rheum"},{"key":"2025090312173897000_6.1.e001042.46","article-title":"ORAL Scan: Effects of the oral JAK inhibitor tofacitinib in combination with methotrexate on patient reported outcomes in a 24-month phase 3 trial of active rheumatoid arthritis [abstract]","volume":"65(Suppl_10)","author":"Strand","year":"2013","journal-title":"Arthritis Rheum"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-001042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:17:52Z","timestamp":1756927072000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-001042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,3]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/rmdopen-2019-001042"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-001042","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}